Skip to main content
Top
Published in: Endocrine Pathology 3/2016

01-09-2016

Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics

Authors: Erik Kouba, Liang Cheng

Published in: Endocrine Pathology | Issue 3/2016

Login to get access

Abstract

Neuroendocrine neoplasms of the urinary bladder are a rare type of tumor that account for a small percentage of urinary bladder neoplasms. These tumors of the urinary bladder range from well-differentiated neuroendocrine neoplasms (carcinoids) to the more aggressive subtypes such as small cell carcinoma. Despite the rarity of the neuroendocrine tumors of the bladder, there has been substantial investigation into the underlying genomic, molecular, and the cellular alterations within this group of neoplasms. Accordingly, these findings are increasingly incorporated into the understanding of clinical aspects of these neoplasms. In this review, we provide an overview of recent literature related to the 2016 World Health Organization Classification of Neuroendocrine Tumors of the Urinary Bladder. Particular emphasis is placed on molecular alterations and recently described gene expression. The neuroendocrine tumors of the urinary bladder are subdivided into four subtypes. Similar to their pulmonary and other extrapulmonary site counterparts, these have different degrees of neuroendocrine differentiation and morphological features. The clinical aspects of four subtypes of neuroendocrine tumor are discussed with emphasis of the most recent developments in diagnosis, treatment, and prognosis. An understanding of molecular basis of neuroendocrine tumors will provide a base of knowledge for future investigations into this group of unusual bladder neoplasms.
Literature
1.
go back to reference Cheng L, Lopez-Beltran A, Bostwick DG. Bladder Pathology. Wiley-Blackwell, Hoboken 2012.CrossRef Cheng L, Lopez-Beltran A, Bostwick DG. Bladder Pathology. Wiley-Blackwell, Hoboken 2012.CrossRef
2.
go back to reference Bostwick DG, Cheng L. Urologic Surgical Pathology, 3rd ed., Elsevier, Philadelphia, 2014. Bostwick DG, Cheng L. Urologic Surgical Pathology, 3rd ed., Elsevier, Philadelphia, 2014.
3.
go back to reference Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004;101:957–62.PubMedCrossRef Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004;101:957–62.PubMedCrossRef
4.
go back to reference Wang X, MacLennan GT, Lopez-Beltran A, Cheng L. Small cell carcinoma of the urinary bladder—histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol 2007;15:8–18.PubMedCrossRef Wang X, MacLennan GT, Lopez-Beltran A, Cheng L. Small cell carcinoma of the urinary bladder—histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol 2007;15:8–18.PubMedCrossRef
5.
go back to reference Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organ. Lyon: International Agency for Research on Cancer (IARC) Press, 2016. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organ. Lyon: International Agency for Research on Cancer (IARC) Press, 2016.
6.
go back to reference Cheng L, Eble JN. Molecular Surgical Pathology. Springer, New York, NY, 2013. Cheng L, Eble JN. Molecular Surgical Pathology. Springer, New York, NY, 2013.
7.
8.
go back to reference Cheng L, Bostwick DG. Essentials of Anatomic Pathology, 4th ed, Springer, New York, NY, 2016. Cheng L, Bostwick DG. Essentials of Anatomic Pathology, 4th ed, Springer, New York, NY, 2016.
9.
go back to reference Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989;64:1347–57.PubMedCrossRef Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989;64:1347–57.PubMedCrossRef
10.
11.
go back to reference Hou CP, Lin YH, Chen CL, Chang PL, Tsui KH. Clinical outcome of primary small cell carcinoma of the urinary bladder. Onco Targets Ther 2013;6:1179–85.PubMedPubMedCentral Hou CP, Lin YH, Chen CL, Chang PL, Tsui KH. Clinical outcome of primary small cell carcinoma of the urinary bladder. Onco Targets Ther 2013;6:1179–85.PubMedPubMedCentral
12.
go back to reference Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP, et al. Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer 2009;96:E30-44.PubMed Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP, et al. Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer 2009;96:E30-44.PubMed
13.
go back to reference Kappers MH, van den Meiracker AH, Alwani RA, Kats E, Baggen MG. Paraganglioma of the urinary bladder. Neth J Med 2008;66:163–5.PubMed Kappers MH, van den Meiracker AH, Alwani RA, Kats E, Baggen MG. Paraganglioma of the urinary bladder. Neth J Med 2008;66:163–5.PubMed
14.
go back to reference Martignoni G, Eble JN. Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature. Arch Pathol Lab Med 2003;127:e22-4.PubMed Martignoni G, Eble JN. Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature. Arch Pathol Lab Med 2003;127:e22-4.PubMed
15.
go back to reference Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C. Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int 2006;56:688–93.PubMedCrossRef Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C. Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int 2006;56:688–93.PubMedCrossRef
16.
go back to reference Shatagopam K, Kaimakliotis HZ, Cheng L, Koch MO. Genitourinary small cell malignancies: prostate and bladder. Future Oncol 2015;11:479–88.PubMedCrossRef Shatagopam K, Kaimakliotis HZ, Cheng L, Koch MO. Genitourinary small cell malignancies: prostate and bladder. Future Oncol 2015;11:479–88.PubMedCrossRef
17.
go back to reference Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, Barocas DA, et al. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol 2014;191:329–34.PubMedCrossRef Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, Barocas DA, et al. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol 2014;191:329–34.PubMedCrossRef
18.
go back to reference Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005;103:1172–8.PubMedCrossRef Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005;103:1172–8.PubMedCrossRef
19.
go back to reference Soriano P, Navarro S, Gil M, Llombart-Bosch A. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch 2004;445:292–7.PubMedCrossRef Soriano P, Navarro S, Gil M, Llombart-Bosch A. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch 2004;445:292–7.PubMedCrossRef
20.
go back to reference Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005;46:57–63.PubMedCrossRef Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005;46:57–63.PubMedCrossRef
21.
go back to reference Trias I, Algaba F, Condom E, Espanol I, Segui J, Orsola I, et al. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001;39:85–90.PubMedCrossRef Trias I, Algaba F, Condom E, Espanol I, Segui J, Orsola I, et al. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001;39:85–90.PubMedCrossRef
22.
go back to reference Byrd-Gloster AL, Khoor A, Glass LF, Messina JL, Whitsett JA, Livingston SK, et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 2000;31:58–62.PubMedCrossRef Byrd-Gloster AL, Khoor A, Glass LF, Messina JL, Whitsett JA, Livingston SK, et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 2000;31:58–62.PubMedCrossRef
23.
go back to reference Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125:228–31.PubMed Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125:228–31.PubMed
24.
go back to reference Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415–20.PubMedCrossRef Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415–20.PubMedCrossRef
25.
go back to reference Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin 2016;32:1013–21.PubMedCrossRef Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin 2016;32:1013–21.PubMedCrossRef
26.
go back to reference Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011;24:1120–7.PubMedPubMedCentralCrossRef Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011;24:1120–7.PubMedPubMedCentralCrossRef
27.
go back to reference Cramer SF, Aikawa M, Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 1981;47:724–30.PubMedCrossRef Cramer SF, Aikawa M, Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 1981;47:724–30.PubMedCrossRef
28.
go back to reference Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533–9.PubMedPubMedCentralCrossRef Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533–9.PubMedPubMedCentralCrossRef
29.
go back to reference Pan CX, Zhang H, Lara PN, Jr., Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther 2006;6:1707–13.PubMedCrossRef Pan CX, Zhang H, Lara PN, Jr., Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther 2006;6:1707–13.PubMedCrossRef
30.
go back to reference Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S, et al. Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis 2015;36:616–21. Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S, et al. Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis 2015;36:616–21.
31.
32.
go back to reference Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT, 3rd, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 2014;7:47.PubMedPubMedCentralCrossRef Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT, 3rd, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 2014;7:47.PubMedPubMedCentralCrossRef
33.
go back to reference Abbosh PH, Wang M, Eble JN, Lopez-Beltran A, Maclennan GT, Montironi R, et al. Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Mod Pathol 2008;21:355–62.PubMedCrossRef Abbosh PH, Wang M, Eble JN, Lopez-Beltran A, Maclennan GT, Montironi R, et al. Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Mod Pathol 2008;21:355–62.PubMedCrossRef
34.
go back to reference Pant-Purohit M, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L. Small cell carcinoma of the urinary bladder. Histol Histopathol 2010;25:217–21.PubMed Pant-Purohit M, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L. Small cell carcinoma of the urinary bladder. Histol Histopathol 2010;25:217–21.PubMed
35.
go back to reference Ahmed S, Neufeld S, Kroczak TJ, Bashir B, Ahmed N, Czaykowski P, et al. Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Center. Cureus 2015;7:e296.PubMedPubMedCentral Ahmed S, Neufeld S, Kroczak TJ, Bashir B, Ahmed N, Czaykowski P, et al. Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Center. Cureus 2015;7:e296.PubMedPubMedCentral
36.
go back to reference Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol 2015;22:549–54.PubMedCrossRef Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol 2015;22:549–54.PubMedCrossRef
37.
go back to reference Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, et al. Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol 2013;36:126–31.PubMedCrossRef Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, et al. Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol 2013;36:126–31.PubMedCrossRef
38.
go back to reference Koga F, Yokoyama M, Fukushima H. Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments. Expert Rev Anticancer Ther 2013;13:1269–79.PubMedCrossRef Koga F, Yokoyama M, Fukushima H. Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments. Expert Rev Anticancer Ther 2013;13:1269–79.PubMedCrossRef
39.
go back to reference Cheng DL, Unger P, Forscher CA, Fine EM. Successful treatment of metastatic small cell carcinoma of the bladder with methotrexate, vinblastine, doxorubicin and cisplatin therapy. J Urol 1995;153:417–9.PubMedCrossRef Cheng DL, Unger P, Forscher CA, Fine EM. Successful treatment of metastatic small cell carcinoma of the bladder with methotrexate, vinblastine, doxorubicin and cisplatin therapy. J Urol 1995;153:417–9.PubMedCrossRef
40.
go back to reference Matsui Y, Fujikawa K, Iwamura H, Oka H, Fukuzawa S, Takeuchi H. Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel. Int J Urol 2002;9:122–4.PubMedCrossRef Matsui Y, Fujikawa K, Iwamura H, Oka H, Fukuzawa S, Takeuchi H. Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel. Int J Urol 2002;9:122–4.PubMedCrossRef
41.
go back to reference Kawahara T, Nishiyama H, Yamamoto S, Kamoto T, Ogawa O. Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder. Int J Urol 2006;13:1251–3.PubMedCrossRef Kawahara T, Nishiyama H, Yamamoto S, Kamoto T, Ogawa O. Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder. Int J Urol 2006;13:1251–3.PubMedCrossRef
42.
go back to reference Eswara JR, Heney NM, Wu CL, McDougal WS. Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder. Urol Int 2015;94:401–5.PubMedCrossRef Eswara JR, Heney NM, Wu CL, McDougal WS. Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder. Urol Int 2015;94:401–5.PubMedCrossRef
43.
go back to reference Koay EJ, Teh BS, Paulino AC, Butler EB. Treatment trends and outcomes of small-cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2012;83:64–70.PubMedCrossRef Koay EJ, Teh BS, Paulino AC, Butler EB. Treatment trends and outcomes of small-cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2012;83:64–70.PubMedCrossRef
44.
go back to reference Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009;27:2592–7.PubMedPubMedCentralCrossRef Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009;27:2592–7.PubMedPubMedCentralCrossRef
45.
go back to reference Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013;64:307–13.PubMedCrossRef Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013;64:307–13.PubMedCrossRef
46.
go back to reference Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, et al. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. Int J Radiat Oncol Biol Phys 2015;92:904–10.PubMedCrossRef Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, et al. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. Int J Radiat Oncol Biol Phys 2015;92:904–10.PubMedCrossRef
47.
go back to reference Ismaili N, Heudel PE, Elkarak F, Kaikani W, Bajard A, Ismaili M, et al. Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol 2009;9:4.PubMedPubMedCentralCrossRef Ismaili N, Heudel PE, Elkarak F, Kaikani W, Bajard A, Ismaili M, et al. Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol 2009;9:4.PubMedPubMedCentralCrossRef
48.
go back to reference Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol 2009;27:101–6.PubMedCrossRef Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol 2009;27:101–6.PubMedCrossRef
49.
go back to reference Nejat RJ, Purohit R, Goluboff ET, Petrylak D, Rubin MA, Benson MC. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urol Oncol 2001;6:53–5.PubMedCrossRef Nejat RJ, Purohit R, Goluboff ET, Petrylak D, Rubin MA, Benson MC. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urol Oncol 2001;6:53–5.PubMedCrossRef
50.
go back to reference Bex A, Sonke GS, Pos FJ, Brandsma D, Kerst JM, Horenblas S. Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol 2010;21:2240–5.PubMedCrossRef Bex A, Sonke GS, Pos FJ, Brandsma D, Kerst JM, Horenblas S. Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol 2010;21:2240–5.PubMedCrossRef
51.
go back to reference Yazici O, Ozdemir NY, Sendur MA, Aksoy S, Zengin N. Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma. Curr Med Res Opin 2014;30:1327–36.PubMedCrossRef Yazici O, Ozdemir NY, Sendur MA, Aksoy S, Zengin N. Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma. Curr Med Res Opin 2014;30:1327–36.PubMedCrossRef
52.
go back to reference Bertaccini A, Marchiori D, Cricca A, Garofalo M, Giovannini C, Manferrari F, et al. Neuroendocrine carcinoma of the urinary bladder: case report and review of the literature. Anticancer Res 2008;28:1369–72.PubMed Bertaccini A, Marchiori D, Cricca A, Garofalo M, Giovannini C, Manferrari F, et al. Neuroendocrine carcinoma of the urinary bladder: case report and review of the literature. Anticancer Res 2008;28:1369–72.PubMed
53.
go back to reference Gupta S, Thompson RH, Boorjian SA, Thapa P, Hernandez LP, Jimenez RE, et al. High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology 2015;47:533–42.PubMedCrossRef Gupta S, Thompson RH, Boorjian SA, Thapa P, Hernandez LP, Jimenez RE, et al. High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology 2015;47:533–42.PubMedCrossRef
54.
go back to reference Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Jr., Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529–53.PubMedCrossRef Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Jr., Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529–53.PubMedCrossRef
55.
go back to reference Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001;116:466–72.PubMedCrossRef Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001;116:466–72.PubMedCrossRef
56.
go back to reference Colarossi C, Pino P, Giuffrida D, Aiello E, Costanzo R, Martinetti D, et al. Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report. Diagn Pathol 2013;8:19.PubMedPubMedCentralCrossRef Colarossi C, Pino P, Giuffrida D, Aiello E, Costanzo R, Martinetti D, et al. Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report. Diagn Pathol 2013;8:19.PubMedPubMedCentralCrossRef
57.
go back to reference Hata S, Tasaki Y. A case of the large cell neuroendocrine carcinoma of the urinary bladder. J Med Case Rep 2013;2013:804136. Hata S, Tasaki Y. A case of the large cell neuroendocrine carcinoma of the urinary bladder. J Med Case Rep 2013;2013:804136.
58.
go back to reference Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, et al. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. Br J Cancer 2015;113:1704–11.PubMedCrossRef Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, et al. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. Br J Cancer 2015;113:1704–11.PubMedCrossRef
59.
go back to reference Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996;148:1531–41.PubMedPubMedCentral Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996;148:1531–41.PubMedPubMedCentral
60.
go back to reference Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol 1998;153:1089–98.PubMedPubMedCentralCrossRef Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol 1998;153:1089–98.PubMedPubMedCentralCrossRef
61.
go back to reference Evans AJ, Al-Maghrabi J, Tsihlias J, Lajoie G, Sweet JM, Chapman WB. Primary large cell neuroendocrine carcinoma of the urinary bladder. Arch Pathol Lab Med 2002;126:1229–32.PubMed Evans AJ, Al-Maghrabi J, Tsihlias J, Lajoie G, Sweet JM, Chapman WB. Primary large cell neuroendocrine carcinoma of the urinary bladder. Arch Pathol Lab Med 2002;126:1229–32.PubMed
62.
go back to reference Abenoza P, Manivel C, Sibley RK. Adenocarcinoma with neuroendocrine differentiation of the urinary bladder. Clinicopathologic, immunohistochemical, and ultrastructural study. Arch Pathol Lab Med 1986;110:1062–6.PubMed Abenoza P, Manivel C, Sibley RK. Adenocarcinoma with neuroendocrine differentiation of the urinary bladder. Clinicopathologic, immunohistochemical, and ultrastructural study. Arch Pathol Lab Med 1986;110:1062–6.PubMed
63.
go back to reference Hailemariam S, Gaspert A, Komminoth P, Tamboli P, Amin M. Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder. Mod Pathol 1998;11:1016–20.PubMed Hailemariam S, Gaspert A, Komminoth P, Tamboli P, Amin M. Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder. Mod Pathol 1998;11:1016–20.PubMed
64.
go back to reference Martin IJ, Vilar DG, Aguado JM, Perello CG, Aliaga MR, Argente VG, et al. Large cell neuroendocrine carcinoma of the urinary bladder. Bibliographic review. Arch Esp Urol 2011;64:105–13.PubMed Martin IJ, Vilar DG, Aguado JM, Perello CG, Aliaga MR, Argente VG, et al. Large cell neuroendocrine carcinoma of the urinary bladder. Bibliographic review. Arch Esp Urol 2011;64:105–13.PubMed
65.
go back to reference Treglia G, Bongiovanni M, Giovanella L. A rare case of small cell neuroendocrine carcinoma of the urinary bladder incidentally detected by F-18-FDG PET/CT. Endocrine 2014;45:156–7.PubMedCrossRef Treglia G, Bongiovanni M, Giovanella L. A rare case of small cell neuroendocrine carcinoma of the urinary bladder incidentally detected by F-18-FDG PET/CT. Endocrine 2014;45:156–7.PubMedCrossRef
66.
go back to reference Iagaru A, Gamie S, Segall G. F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. Clin Nucl Med 2006;31:476–8.PubMedCrossRef Iagaru A, Gamie S, Segall G. F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. Clin Nucl Med 2006;31:476–8.PubMedCrossRef
67.
go back to reference Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. J Thorac Oncol 2015;10:1133–41.PubMedPubMedCentralCrossRef Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. J Thorac Oncol 2015;10:1133–41.PubMedPubMedCentralCrossRef
68.
go back to reference Akamatsu S, Kanamaru S, Ishihara M, Sano T, Soeda A, Hashimoto K. Primary large cell neuroendocrine carcinoma of the urinary bladder. Int J Urol 2008;15:1080–3.PubMedCrossRef Akamatsu S, Kanamaru S, Ishihara M, Sano T, Soeda A, Hashimoto K. Primary large cell neuroendocrine carcinoma of the urinary bladder. Int J Urol 2008;15:1080–3.PubMedCrossRef
69.
70.
go back to reference Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer 2016;95:82–7.PubMedCrossRef Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer 2016;95:82–7.PubMedCrossRef
71.
go back to reference Lee WJ, Kim CH, Chang SE, Lee MW, Choi JH, Moon KC, et al. Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. Am J Dermatopathol 2009;31:166–9.PubMedCrossRef Lee WJ, Kim CH, Chang SE, Lee MW, Choi JH, Moon KC, et al. Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. Am J Dermatopathol 2009;31:166–9.PubMedCrossRef
72.
go back to reference Colby TV. Carcinoid tumor of the bladder. A case report. Arch Pathol Lab Med 1980;104:199–200.PubMed Colby TV. Carcinoid tumor of the bladder. A case report. Arch Pathol Lab Med 1980;104:199–200.PubMed
73.
go back to reference Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol 2011;35:442–6.PubMed Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol 2011;35:442–6.PubMed
74.
75.
go back to reference Wang M, Peng J, Yang W, Chen W, Mo S, Cai S. Prognostic analysis for carcinoid tumours of the rectum: a single institutional analysis of 106 patients. Colorectal Dis 2011;13:150–3.PubMedCrossRef Wang M, Peng J, Yang W, Chen W, Mo S, Cai S. Prognostic analysis for carcinoid tumours of the rectum: a single institutional analysis of 106 patients. Colorectal Dis 2011;13:150–3.PubMedCrossRef
76.
go back to reference Zozumi M, Nakai M, Matsuda I, Hao H, Ueda Y, Nojima M, et al. Primary carcinoid tumor of the urinary bladder with prominent subnuclear eosinophilic granules. Pathol Res Pract 2012;208:109–12.PubMedCrossRef Zozumi M, Nakai M, Matsuda I, Hao H, Ueda Y, Nojima M, et al. Primary carcinoid tumor of the urinary bladder with prominent subnuclear eosinophilic granules. Pathol Res Pract 2012;208:109–12.PubMedCrossRef
77.
go back to reference McCabe JE, Das S, Dowling P, Hamid BN, Pettersson BA. Oncocytic carcinoid tumour of the bladder. J Clin Pathol 2005;58:446–7.PubMedPubMedCentral McCabe JE, Das S, Dowling P, Hamid BN, Pettersson BA. Oncocytic carcinoid tumour of the bladder. J Clin Pathol 2005;58:446–7.PubMedPubMedCentral
78.
go back to reference Sugihara A, Kajio K, Yoshimoto T, Tsujimura T, Iwasaki T, Yamada N, et al. Primary carcinoid tumor of the urinary bladder. Int Urol Nephrol 2002;33:53–7.PubMedCrossRef Sugihara A, Kajio K, Yoshimoto T, Tsujimura T, Iwasaki T, Yamada N, et al. Primary carcinoid tumor of the urinary bladder. Int Urol Nephrol 2002;33:53–7.PubMedCrossRef
79.
go back to reference Stanfield BL, Grimes MM, Kay S. Primary carcinoid tumor of the bladder arising beneath an inverted papilloma. Arch Pathol Lab Med 1994;118:666–7.PubMed Stanfield BL, Grimes MM, Kay S. Primary carcinoid tumor of the bladder arising beneath an inverted papilloma. Arch Pathol Lab Med 1994;118:666–7.PubMed
80.
go back to reference Baydar DE, Tasar C. Carcinoid tumor in the urinary bladder: unreported features. Am J Surg Pathol 2011;35:1754–7.PubMedCrossRef Baydar DE, Tasar C. Carcinoid tumor in the urinary bladder: unreported features. Am J Surg Pathol 2011;35:1754–7.PubMedCrossRef
81.
go back to reference Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 2014;5:3518.PubMedPubMedCentralCrossRef Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 2014;5:3518.PubMedPubMedCentralCrossRef
82.
go back to reference Murali R, Kneale K, Lalak N, Delprado W. Carcinoid tumors of the urinary tract and prostate. Arch Pathol Lab Med 2006;130:1693–706.PubMed Murali R, Kneale K, Lalak N, Delprado W. Carcinoid tumors of the urinary tract and prostate. Arch Pathol Lab Med 2006;130:1693–706.PubMed
83.
go back to reference Mascolo M, Altieri V, Mignogna C, Napodano G, De Rosa G, Insabato L. Calcitonin-producing well-differentiated neuroendocrine carcinoma (carcinoid tumor) of the urinary bladder: case report. BMC Cancer 2005;5:88.PubMedPubMedCentralCrossRef Mascolo M, Altieri V, Mignogna C, Napodano G, De Rosa G, Insabato L. Calcitonin-producing well-differentiated neuroendocrine carcinoma (carcinoid tumor) of the urinary bladder: case report. BMC Cancer 2005;5:88.PubMedPubMedCentralCrossRef
84.
go back to reference Walker BF, Someren A, Kennedy JC, Nicholas EM. Primary carcinoid tumor of the urinary bladder. Arch Pathol Lab Med 1992;116:1217–20.PubMed Walker BF, Someren A, Kennedy JC, Nicholas EM. Primary carcinoid tumor of the urinary bladder. Arch Pathol Lab Med 1992;116:1217–20.PubMed
85.
go back to reference Chin NW, Marinescu AM, Fani K. Composite adenocarcinoma and carcinoid tumor of urinary bladder. Urology 1992;40:249–52.PubMedCrossRef Chin NW, Marinescu AM, Fani K. Composite adenocarcinoma and carcinoid tumor of urinary bladder. Urology 1992;40:249–52.PubMedCrossRef
86.
go back to reference Hemal AK, Singh I, Pawar R, Kumar M, Taneja P. Primary malignant bladder carcinoid--a diagnostic and management dilemma. Urology 2000;55:949. Hemal AK, Singh I, Pawar R, Kumar M, Taneja P. Primary malignant bladder carcinoid--a diagnostic and management dilemma. Urology 2000;55:949.
87.
go back to reference Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Neumann RM, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer 2000;88:844–52.PubMedCrossRef Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Neumann RM, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer 2000;88:844–52.PubMedCrossRef
88.
go back to reference Henderson SJ, Kearns PJ, Tong CM, Reddy M, Khurgin J, Bickell M, et al. Patients with urinary bladder paragangliomas: a compiled case series from a literature review for clinical management. Urology 2015;85:e25-9.PubMedCrossRef Henderson SJ, Kearns PJ, Tong CM, Reddy M, Khurgin J, Bickell M, et al. Patients with urinary bladder paragangliomas: a compiled case series from a literature review for clinical management. Urology 2015;85:e25-9.PubMedCrossRef
89.
go back to reference Zhou M, Epstein JI, Young RH. Paraganglioma of the urinary bladder: a lesion that may be misdiagnosed as urothelial carcinoma in transurethral resection specimens. Am J Surg Pathol 2004;28:94–100.PubMedCrossRef Zhou M, Epstein JI, Young RH. Paraganglioma of the urinary bladder: a lesion that may be misdiagnosed as urothelial carcinoma in transurethral resection specimens. Am J Surg Pathol 2004;28:94–100.PubMedCrossRef
90.
91.
go back to reference Beilan JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol 2013;13:22.PubMedPubMedCentralCrossRef Beilan JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol 2013;13:22.PubMedPubMedCentralCrossRef
92.
go back to reference Dixon JS, Gosling JA, Canning DA, Gearhart JP. An immunohistochemical study of human postnatal paraganglia associated with the urinary bladder. J Anat 1992;181 (Pt 3):431–6.PubMedPubMedCentral Dixon JS, Gosling JA, Canning DA, Gearhart JP. An immunohistochemical study of human postnatal paraganglia associated with the urinary bladder. J Anat 1992;181 (Pt 3):431–6.PubMedPubMedCentral
93.
go back to reference Fletcher TF, Bradley WE. Neuroanatomy of the bladder-urethra. J Urol 1978;119:153–60.PubMed Fletcher TF, Bradley WE. Neuroanatomy of the bladder-urethra. J Urol 1978;119:153–60.PubMed
94.
95.
go back to reference Giubellino A, Lara K, Martucci V, Huynh T, Agarwal P, Pacak K, et al. Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. Am J Surg Pathol 2015;39:1488–92.PubMedCrossRef Giubellino A, Lara K, Martucci V, Huynh T, Agarwal P, Pacak K, et al. Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. Am J Surg Pathol 2015;39:1488–92.PubMedCrossRef
96.
go back to reference Honma K. Paraganglia of the urinary bladder. An autopsy study. Zentralbl Pathol 1994;139:465–9.PubMed Honma K. Paraganglia of the urinary bladder. An autopsy study. Zentralbl Pathol 1994;139:465–9.PubMed
97.
go back to reference Martucci VL, Lorenzo ZG, Weintraub M, del Rivero J, Ling A, Merino M, et al. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol 2015;33:167 e13-20.PubMedPubMedCentralCrossRef Martucci VL, Lorenzo ZG, Weintraub M, del Rivero J, Ling A, Merino M, et al. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol 2015;33:167 e13-20.PubMedPubMedCentralCrossRef
98.
go back to reference Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91:827–36.PubMedCrossRef Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91:827–36.PubMedCrossRef
99.
go back to reference Milunsky JM, Maher TA, Michels VV, Milunsky A. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am J Med Genet 2001;100:311–4.PubMedCrossRef Milunsky JM, Maher TA, Michels VV, Milunsky A. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am J Med Genet 2001;100:311–4.PubMedCrossRef
100.
go back to reference Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003;63:5615–21.PubMed Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003;63:5615–21.PubMed
101.
go back to reference van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764–71.PubMedPubMedCentralCrossRef van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764–71.PubMedPubMedCentralCrossRef
102.
go back to reference Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005;1:72–80.PubMedCrossRef Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005;1:72–80.PubMedCrossRef
103.
go back to reference Lima J, Feijao T, Ferreira da Silva A, Pereira-Castro I, Fernandez-Ballester G, Maximo V, et al. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab 2007;92:4853–64.PubMedCrossRef Lima J, Feijao T, Ferreira da Silva A, Pereira-Castro I, Fernandez-Ballester G, Maximo V, et al. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab 2007;92:4853–64.PubMedCrossRef
104.
go back to reference Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002;87:4771–4.PubMedCrossRef Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002;87:4771–4.PubMedCrossRef
105.
go back to reference Jimenez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006;91:2851–8.PubMedCrossRef Jimenez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006;91:2851–8.PubMedCrossRef
106.
go back to reference Schaefer IM, Gunawan B, Fuzesi L, Blech M, Frasunek J, Loertzer H. Chromosomal imbalances in urinary bladder paraganglioma. Cancer Genet Cytogenet 2010;203:341–4.PubMedCrossRef Schaefer IM, Gunawan B, Fuzesi L, Blech M, Frasunek J, Loertzer H. Chromosomal imbalances in urinary bladder paraganglioma. Cancer Genet Cytogenet 2010;203:341–4.PubMedCrossRef
107.
go back to reference Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 2000;156:651–9.PubMedPubMedCentralCrossRef Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 2000;156:651–9.PubMedPubMedCentralCrossRef
108.
go back to reference August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol 2004;17:1119–28.PubMedCrossRef August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol 2004;17:1119–28.PubMedCrossRef
109.
go back to reference Costa MH, Ortiga-Carvalho TM, Violante AD, Vaisman M. Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol 2015;6:126.CrossRef Costa MH, Ortiga-Carvalho TM, Violante AD, Vaisman M. Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol 2015;6:126.CrossRef
110.
go back to reference Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014;14:108–19.PubMedCrossRef Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014;14:108–19.PubMedCrossRef
111.
go back to reference de Cubas AA, Korpershoek E, Inglada-Perez L, Letouze E, Curras-Freixes M, Fernandez AF, et al. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clin Cancer Res 2015;21:3020–30.PubMedCrossRef de Cubas AA, Korpershoek E, Inglada-Perez L, Letouze E, Curras-Freixes M, Fernandez AF, et al. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clin Cancer Res 2015;21:3020–30.PubMedCrossRef
112.
go back to reference de Cubas AA, Leandro-Garcia LJ, Schiavi F, Mancikova V, Comino-Mendez I, Inglada-Perez L, et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer 2013;20:477–93.PubMedCrossRef de Cubas AA, Leandro-Garcia LJ, Schiavi F, Mancikova V, Comino-Mendez I, Inglada-Perez L, et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer 2013;20:477–93.PubMedCrossRef
113.
go back to reference Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun 2015;6:6044.PubMedPubMedCentralCrossRef Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun 2015;6:6044.PubMedPubMedCentralCrossRef
114.
go back to reference Flynn A, Benn D, Clifton-Bligh R, Robinson B, Trainer AH, James P, et al. The genomic landscape of phaeochromocytoma. J Pathol 2015;236:78–89.PubMedCrossRef Flynn A, Benn D, Clifton-Bligh R, Robinson B, Trainer AH, James P, et al. The genomic landscape of phaeochromocytoma. J Pathol 2015;236:78–89.PubMedCrossRef
115.
go back to reference Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011;20:3974–85.PubMedCrossRef Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011;20:3974–85.PubMedCrossRef
116.
go back to reference Bohn OL, Pardo-Castillo E, Fuertes-Camilo M, Rios-Luna NP, Martinez A, Sanchez-Sosa S. Urinary bladder paraganglioma in childhood: a case report and review of the literature. Pediatr Dev Pathol 2011;14:327–32.PubMedCrossRef Bohn OL, Pardo-Castillo E, Fuertes-Camilo M, Rios-Luna NP, Martinez A, Sanchez-Sosa S. Urinary bladder paraganglioma in childhood: a case report and review of the literature. Pediatr Dev Pathol 2011;14:327–32.PubMedCrossRef
117.
go back to reference Lai Y, Chen D, Yu Z, Ni L, Yang S. Non-functioning paraganglioma of the urinary bladder: A case report and review of the literature. Oncol Lett 2014;7:891–3.PubMedPubMedCentral Lai Y, Chen D, Yu Z, Ni L, Yang S. Non-functioning paraganglioma of the urinary bladder: A case report and review of the literature. Oncol Lett 2014;7:891–3.PubMedPubMedCentral
118.
go back to reference Yadav R, Das AK, Kumar R. Malignant non-functional paraganglioma of the bladder presenting with azotemia. Int Urol Nephrol 2007;39:449–51.PubMedCrossRef Yadav R, Das AK, Kumar R. Malignant non-functional paraganglioma of the bladder presenting with azotemia. Int Urol Nephrol 2007;39:449–51.PubMedCrossRef
119.
go back to reference Peng C, Bu S, Xiong S, Wang K, Li H. Non-functioning paraganglioma occurring in the urinary bladder: A case report and review of the literature. Oncol Lett 2015;10:321–4.PubMedPubMedCentral Peng C, Bu S, Xiong S, Wang K, Li H. Non-functioning paraganglioma occurring in the urinary bladder: A case report and review of the literature. Oncol Lett 2015;10:321–4.PubMedPubMedCentral
120.
go back to reference Moyana TN, Kontozoglou T. Urinary bladder paragangliomas. An immunohistochemical study. Arch Pathol Lab Med 1988;112:70–2.PubMed Moyana TN, Kontozoglou T. Urinary bladder paragangliomas. An immunohistochemical study. Arch Pathol Lab Med 1988;112:70–2.PubMed
121.
go back to reference Kovacs K, Bell D, Gardiner GW, Honey RJ, Goguen J, Rotondo F. Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators. Endocr Pathol 2005;16:363–9.PubMedCrossRef Kovacs K, Bell D, Gardiner GW, Honey RJ, Goguen J, Rotondo F. Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators. Endocr Pathol 2005;16:363–9.PubMedCrossRef
122.
go back to reference So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol 2013;26:1365–70.PubMedCrossRef So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol 2013;26:1365–70.PubMedCrossRef
123.
go back to reference Menon S, Goyal P, Suryawanshi P, Tongaonkar H, Joshi A, Bakshi G, et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol 2014;57:19–23.PubMedCrossRef Menon S, Goyal P, Suryawanshi P, Tongaonkar H, Joshi A, Bakshi G, et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol 2014;57:19–23.PubMedCrossRef
124.
go back to reference Grignon DJ, Ro JY, Mackay B, Ordonez NG, el-Naggar A, Molina TJ, et al. Paraganglioma of the urinary bladder: immunohistochemical, ultrastructural, and DNA flow cytometric studies. Hum Pathol 1991;22:1162–9.PubMedCrossRef Grignon DJ, Ro JY, Mackay B, Ordonez NG, el-Naggar A, Molina TJ, et al. Paraganglioma of the urinary bladder: immunohistochemical, ultrastructural, and DNA flow cytometric studies. Hum Pathol 1991;22:1162–9.PubMedCrossRef
125.
go back to reference Wang H, Ye H, Guo A, Wei Z, Zhang X, Zhong Y, et al. Bladder paraganglioma in adults: MR appearance in four patients. Eur J Radiol 2011;80:e217-20.PubMedCrossRef Wang H, Ye H, Guo A, Wei Z, Zhang X, Zhong Y, et al. Bladder paraganglioma in adults: MR appearance in four patients. Eur J Radiol 2011;80:e217-20.PubMedCrossRef
126.
go back to reference Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant Pheochromocytoma - Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine. Ann Intern Med 1988;109:267–73. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant Pheochromocytoma - Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine. Ann Intern Med 1988;109:267–73.
127.
go back to reference Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162–8.PubMedPubMedCentralCrossRef Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162–8.PubMedPubMedCentralCrossRef
Metadata
Title
Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics
Authors
Erik Kouba
Liang Cheng
Publication date
01-09-2016
Publisher
Springer US
Published in
Endocrine Pathology / Issue 3/2016
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9444-5

Other articles of this Issue 3/2016

Endocrine Pathology 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine